Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019
May 16, 2019
New data on Opdivo (nivolumab) plus Yervoy (ipilimumab)
in patients with advanced hepatocellular carcinoma and in melanoma
patients with symptomatic brain metastases
New long-term survival data and health outcomes research on Opdivo
in combination with Yervoy in advanced melanoma
Eighteen-month efficacy results for Empliciti (elotuzumab)
plus pomalidomide and low-dose dexamethasone for relapsed/refractory
multiple myeloma
Translational research exploring the use of novel technologies and
artificial intelligence to understand the association of inflammation
gene signatures with tumor immune cells
PRINCETON, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt; lt;a href="https://twitter.com/hashtag/ASCO19?src=hash" target="_blank"gt;#ASCO19lt;/agt;–Bristol-Myers
Squibb Company (NYSE:BMY) today announced the presentation of data
from across the company’s oncology portfolio at the American Society of
Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4,
and the 24th Annual Congress of the European Hematology
Association (EHA) in Amsterdam, June 13-16. Data from over 90
Company-sponsored studies, investigator-sponsored studies and
collaborations evaluating oncology compounds and early translational
medicine across 20 types of cancer will be featured at the two meetings.
Presentations will highlight the role of Immuno-Oncology (I-O)
monotherapy and combination approaches in improving survival and quality
of life outcomes, as well as translational research investigating novel
biomarkers and diagnostics to aid in the selection of tailored
treatments for each patient based on their unique disease biology.
2019 ASCO Annual Meeting – Highlights of Bristol-Myers Squibb data
include:
*All times noted are Central Daylight Time
Hepatocellular Carcinoma
-
Primary efficacy and safety results from the Phase 1/2 CheckMate -040
study evaluating the combination of Opdivo (nivolumab) plus Yervoy
(ipilimumab) in patients with advanced hepatocellular carcinoma,
the most common type of liver cancer, will be presented. These data
(Abstract #4012), including objective response rate and overall
survival, will be featured in a poster display on Monday, June 3 from
8-11 AM CDT, and in a poster discussion from 3-4:30 PM CDT.
Melanoma
-
Safety and efficacy of Opdivo in combination with Yervoy
in patients with symptomatic melanoma brain metastases (Abstract
#9501) will be featured in an oral session on Tuesday, June 4, from
9:45 AM-12:45 PM CDT. -
New long-term survival data and health outcomes research evaluating Opdivo
in combination with Yervoy in advanced melanoma—in terms of
survival outcomes (CA209-004, Abstract #9533), quality of life after
four years and during the treatment-free interval following
discontinuation of therapy (CheckMate -067, Abstracts #9551 and
#9568), and treatment-free survival (pooled data from CheckMate -067
and -069, Abstract # 9550) – will be featured in a poster display on
Monday, June 3 from 1:15-4:15 PM CDT.
Renal Cell Carcinoma
-
Safety and efficacy of Opdivo in combination with Yervoy
in patients with asymptomatic advanced renal cell carcinoma brain
metastases (Abstract #4517) will be featured in a poster display on
Monday, June 3 from 1:15-4:15 PM CDT, and in a poster discussion from
4:30-6 PM CDT.
Translational Medicine and Tumor Biology
-
Translational data to identify potentially predictive biomarkers and
expand translational research capabilities will be presented. Through
the use of gene expression profiling (GEP) and machine-learning
modeling, a novel, tumor-associated inflammation gene signature was
identified through correlative, immunohistochemistry assessment of CD8
expression on T cells. This CD8-derived signature was then used to
assess inflammation of the tumor microenvironment across 12 tumor
types (Abstract #2593). Additionally, using an innovative artificial
intelligence-based approach, combined with T-cell localization gene
signatures by GEP, researchers quantified the abundance of immune
cells and their spatial location within the tumor microenvironment
(Abstract #2594). Both abstracts will be featured in a poster session
on Saturday, June 1 from 8-11 AM CDT.
24th Annual Congress of the EHA – Highlights
of Bristol-Myers Squibb data include:
*All times noted are
Central European Standard Time
Multiple Myeloma
-
Extended 18-month follow-up data from the Phase 2 ELOQUENT-3 trial
(Abstract #PS1370) evaluating the addition of Empliciti (elotuzumab)
to pomalidomide and low-dose dexamethasone in relapsed/refractory
(R/R) multiple myeloma, including a descriptive overall survival
analysis for the combination, will be featured in a poster session on
Saturday, June 15 from 5:30-7 PM CEST.
Classical Hodgkin and Non-Hodgkin Lymphoma
-
Updated safety and efficacy results in two patient subgroups from the
Phase 2 CheckMate -744 study, the first risk-stratified,
response-adapted study of Opdivo and ADCETRIS (brentuximab
vedotin), followed by ADCETRIS and bendamustine for suboptimal
response, in children, adolescents and young adults with R/R classical
Hodgkin lymphoma (cHL), prior to autologous stem cell transplantation
(Abstract #S822) will be presented in an oral presentation on
Saturday, June 15 from 12:30-12:45 PM CEST. -
Two-year results from cohort D of the Phase 2 CheckMate -205 study,
evaluating Opdivo plus doxorubicin, vinblastine and dacarbazine
in patients with newly diagnosed advanced-stage cHL (Abstract #S821),
will be presented in an oral presentation on Saturday, June 15 from
12:15-12:30 PM CEST. -
A full analysis of the Phase 1/2 CheckMate -436 study, evaluating Opdivo
and ADCETRIS in patients with R/R primary mediastinal large B-cell
lymphoma (Abstract #S1601), will be presented in an oral presentation
on Sunday, June 16 from 9-9:15 AM CEST.
2019 ASCO Annual Meeting – Company-sponsored and collaborative data
include:
*All times noted are Central Daylight Time
Gastrointestinal Malignancies
-
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients
(pts) with advanced hepatocellular carcinoma (aHCC): Results from
CheckMate 040
Author: Yau
Abstract: #4012
Poster
Discussion Session: Gastrointestinal (Noncolorectal) Cancer
Monday,
June 3, Poster Display: 8-11 AM, Hall A
Discussion: 3-4:30 PM,
Arie Crown Theater
-
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L)
therapy in microsatellite instability-high/DNA mismatch repair
deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical
update
Author: Lenz
Abstract: #3521
Poster
Session: Gastrointestinal (Colorectal) Cancer
Monday, June 3,
Poster Display: 8-11 AM, Hall A
Melanoma
-
Long-term follow-up of CA209-004: A phase I dose-escalation study
of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with
advanced melanoma
Author: Atkins
Abstract: #9533
Poster
Session: Melanoma/Skin Cancers
Monday, June 3, Poster Display:
1:15-4:15 PM, Hall A
-
Sensitivity of treatment-free survival (TFS), a novel outcome, to
subgroup analyses of patients (pts) with advanced melanoma (MEL)
treated with immune checkpoint inhibitors (ICI)
Author:
Mantia
Abstract: #9550
Poster Session: Melanoma/Skin Cancers
Monday,
June 3, Poster Display: 1:15-4:15 PM, Hall A
-
Patient-reported quality of life (QoL) of advanced melanoma
patients in a Phase 3 study of nivolumab (NIVO) with or without
ipilimumab (IPI) versus IPI: CheckMate 067 4-year data
Author:
Schadendorf
Abstract: #9551
Poster Session: Melanoma/Skin
Cancers
Monday, June 3, Poster Display: 1:15-4:15 PM, Hall A
-
Quality of life (QoL) and symptom burden in patients (pts) with
advanced melanoma during the treatment-free interval (TFI) after
discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI)
Author:
Taylor
Abstract: #9568
Poster Session: Melanoma/Skin Cancers
Monday,
June 3, Poster Display: 1:15-4:15 PM, Hall A
-
An analysis of nivolumab-mediated adverse events and association
with clinical efficacy in resected stage III or IV melanoma (CheckMate
238)
Author: Mandala
Abstract: #9584
Poster
Session: Melanoma/Skin Cancers
Monday, June 3, Poster Display:
1:15-4:15 PM, Hall A
-
Efficacy and safety of the combination of nivolumab (NIVO) plus
ipilimumab (IPI) in patients with symptomatic melanoma brain
metastases (CheckMate 204)
Author: Tawbi
Abstract: #9501
Oral
Session: Melanoma/Skin Cancers
Tuesday, June 4, 9:45 AM-12:45 PM,
S406
Presentation: 9:57-10:09 AM, S406
Genitourinary Malignancies
-
CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or
sunitinib in IMDC intermediate/poor-risk patients with previously
untreated advanced renal cell carcinoma with sarcomatoid features
Author:
McDermott
Abstract: #4513
Poster Discussion Session:
Genitourinary (Nonprostate) Cancer
Monday, June 3, Poster
Display: 1:15-4:15 PM, Hall A
Discussion: 4:30-6 PM, Hall D2
-
Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in
patients with advanced renal cell carcinoma (aRCC) with brain
metastases: Interim analysis of CheckMate 920
Author:
Emamekhoo
Abstract: #4517
Poster Discussion Session:
Genitourinary (Nonprostate) Cancer
Monday, June 3, Poster
Display: 1:15-4:15 PM, Hall A
Discussion: 4:30-6 PM, Hall D2
-
Consistent efficacy of nivolumab plus ipilimumab across number of
International Metastatic Database Consortium (IMDC) risk factors in
CheckMate 214
Author: Escudier
Abstract: #4575
Poster
Session: Genitourinary (Nonprostate) Cancer
Monday, June 3,
Poster Display: 1:15-4:15 PM, Hall A
-
Clinical and economic outcomes associated with sequential treatment
in patients with advanced renal cell carcinoma (aRCC)
Author:
Regan
Abstract: #4566
Poster Session: Genitourinary
(Nonprostate) Cancer
Monday, June 3, Poster Display: 1:15-4:15
PM, Hall A
-
Nivolumab monotherapy in patients with advanced platinum-resistant
urothelial carcinoma: Efficacy and safety update from CheckMate 275
Author:
Siefker-Radtke
Abstract: #4524
Poster Session: Genitourinary
(Nonprostate) Cancer
Monday, June 3, Poster Display: 1:15-4:15
PM, Hall A
-
Real-world outcomes with IO therapies: A prospective observational
cohort study in patients (pts) with advanced melanoma (OPTIMIzE)
Author:
Kirkwood
Abstract: #e14144
Online Only
Translational Medicine and Biomarkers
-
Serum IL-6 and CRP as prognostic factors in melanoma patients
receiving single agent and combination checkpoint inhibition
Author:
Weber
Abstract: #100
Clinical Science Symposium: Fine-Tuning
Checkpoint Inhibition: Biomarkers of Response and Resistance
Saturday,
June 1, Clinical Science Symposium: 8-9:30 AM, Hall D1
Presentation:
8-8:12 AM, Hall D1
-
Development of a baseline prognostic cytokine signature that
correlates with nivolumab (NIVO) clearance (CL): Translational
pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with
renal cell carcinoma (RCC)
Author: Wang
Abstract: #2544
Poster
Session: Developmental Immunotherapy and Tumor Immunobiology
Saturday,
June 1, Poster Display: 8-11 AM, Hall A
-
Association of an inflammatory gene signature with CD8 expression
by immunohistochemistry (IHC) in multiple tumor types
Author:
Szabo
Abstract: #2593
Poster Session: Developmental
Immunotherapy and Tumor Immunobiology
Saturday, June 1, Poster
Display: 8-11 AM, Hall A
-
CD8+ T cells in tumor parenchyma and stroma by image analysis (IA)
and gene expression profiling (GEP): Potential biomarkers for
immuno-oncology (I-O) therapy
Author: Szabo
Abstract:
#2594
Poster Session: Developmental Immunotherapy and Tumor
Immunobiology
Saturday, June 1, Poster Display: 8-11 AM, Hall A
-
Association of human endogenous retrovirus (hERV) expression with
clinical efficacy of PD-1 blockade in metastatic clear cell renal cell
carcinoma (mccRCC)
Author: Pignon
Abstract: #4568
Poster
Session: Genitourinary (Nonprostate) Cancer
Monday, June 3,
Poster Display: 1:15-4:15 PM, Hall A
New and Early Assets
-
Baseline tumor-immune signatures associated with response to
bempegaldesleukin (NKTR-214) and nivolumab
Author: Hurwitz
Abstract:
#2623
Poster Session: Developmental Immunotherapy and Tumor
Immunobiology
Saturday, June 1, Poster Display: 8-11 AM, Hall A
-
CA224-060: A randomized, open label, phase II trial of relatlimab
(anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with
chemotherapy as first-line treatment in patients with gastric or
gastroesophageal junction adenocarcinoma
Author: Feeney
Abstract:
#TPS4143
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Monday,
June 3, Poster Display: 8-11 AM, Hall A
-
CA045-001: A phase III, randomized, open label study of
bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO
monotherapy in patients (pts) with previously untreated, unresectable
or metastatic melanoma (MEL)
Author: Khushalani
Abstract:
#TPS9601
Poster Session: Melanoma/Skin Cancers
Monday, June
3, Poster Display: 1:15-4:15 PM, Hall A
-
A phase III randomized open label study comparing bempegaldesleukin
(NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator’s
choice) in patients with previously untreated advanced renal cell
carcinoma
Author: Tannir
Abstract: #TPS4595
Poster
Session: Genitourinary (Nonprostate) Cancer
Monday, June 3,
Poster Display: 1:15-4:15 PM, Hall A
-
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone
or in combination with nivolumab (NIVO) ± BMS-986205 in
cisplatin-eligible muscle invasive bladder cancer (MIBC)
Author:
Sonpavde
Abstract: #TPS4587
Poster Session: Genitourinary
(Nonprostate) Cancer
Monday, June 3, Poster Display: 1:15-4:15
PM, Hall A
Clinical Collaborations
-
Preliminary immunogenicity, safety, and efficacy of JNJ-64041757
(JNJ-757) in non-small cell lung cancer (NSCLC): Results from two
phase 1 studies
Author: Brahmer
Abstract: #9093
Poster
Session: Lung Cancer-Non-Small Cell Metastatic
Sunday, June 2,
Poster Display: 8-11 AM, Hall A
-
An open label, multicenter, phase I/II study of RP1 as a single
agent and in combination with PD1 blockade in patients with solid
tumors
Author: Middleton
Abstract: #TPS2671
Poster
Session: Developmental Immunotherapy and Tumor Immunobiology
Saturday,
June 1, Poster Display: 8-11 AM, Hall A
-
Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ±
ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC
Author:
Malhotra
Abstract: #8516
Poster Session: Lung
Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Sunday,
June 2, Poster Display: 8-11 AM; Hall A
Discussion: 11:15
AM–12:45 PM, S406
24th Congress of the EHA – Company-sponsored
and collaborative data include:
*All times noted are Central
European Summer Time
Lymphoma
-
Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly
Diagnosed Advanced-Stage Classical Hodgkin Lymphoma: 2-Year Extended
Follow-Up From Cohort D of the Phase 2 CheckMate 205 Study
Author:
Domingo-Domènech
Abstract: #S821
Oral Session: Hodgkin
lymphoma – Clinical
Saturday, June 15, 11:30 AM-12:45 PM, Hall 5
Presentation:
12:15-12:30 PM, Hall 5
-
Nivolumab and Brentuximab Vedotin-Based, Response-Adapted Treatment
in Primary Refractory and in Pediatric Patients with
Relapsed/Refractory Classical Hodgkin Lymphoma in CheckMate 744
Author:
LeBlanc
Abstract: #S822
Oral Session: Hodgkin lymphoma –
Clinical
Saturday, June 15, 11:30 AM-12:45 PM, Hall 5
Presentation:
12:30-12:45 PM, Hall 5
-
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory
Primary Mediastinal Large B-cell Lymphoma: Efficacy and Safety Results
from the Phase 2 CheckMate 436 Study
Author: Zinzani
Abstract:
#S1601
Oral Session: Aggressive lymphomas – First line,
combination therapy and real-life data
Sunday, June 16, 8-9:15
AM, Hall 5
Presentation: 9-9:15 AM, Hall 5
Multiple Myeloma
-
Elotuzumab Plus Pomalidomide and Dexamethasone for
Relapsed/Refractory Multiple Myeloma: Efficacy Results After
Additional Follow-Up of the Phase 2, Randomized ELOQUENT-3 Study
Author:
Dimopoulos
Abstract: #PS1370
Poster Session: Myeloma and
other monoclonal gammopathies – Clinical
Saturday, June 15,
5:30-7 PM, Poster Area
-
Investigating Mechanisms of Elotuzumab and Lenalidomide in Multiple
Myeloma
Author: Richardson
Abstract: #PF568
Poster
Session: Myeloma and other monoclonal gammopathies – Biology &
Translational Research
Friday, June 14, 5:30-7 PM, Poster Area
-
Use of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple
Myeloma in Four European Countries – Findings From PREAMBLE
Author:
Moreau
Abstract: #PS1405
Poster Session: Myeloma and other
monoclonal gammopathies – Clinical
Saturday, June 15, 5:30-7 PM,
Poster Area
Leukemia
-
DASCERN 2-Year Extended Follow-Up of Dasatinib Efficacy and Safety
in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase
(CML-CP) Who Have Suboptimal Responses to 3 Months of Imatinib
Author:
Saglio
Abstract: #PF405
Poster Session: Chronic myeloid
leukemia – Clinical
Friday, June 14, 5:30-7 PM, Poster Area
-
DASFREE: 2-Year Update: Dasatinib Discontinuation in Patients (pts)
with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep
Molecular Response (DMR)
Author: Shah
Abstract: #PF408
Poster
Session: Chronic myeloid leukemia – Clinical
Friday, June 14,
5:30-7 PM, Poster Area
-
Growth Rate and Endocrine Effects of Dasatinib Therapy Observed in
Retrospective Analysis of a Phase II Clinical Trial for Pediatric
Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Author:
Patterson
Abstract: #PF416
Poster Session: Chronic myeloid
leukemia – Clinical
Friday, June 14, 5:30-7 PM, Poster Area
-
Dosing Patterns of Dasatinib and Nilotinib Use in SIMPLICITY, an
Observational Study in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
Patients (pts) in Routine Clinical Practice
Author: Cortes
Abstract:
#PS1181
Poster Session: Chronic myeloid leukemia – Clinical
Saturday,
June 15, 5:30-7 PM, Poster Area
Bristol-Myers Squibb: Advancing Oncology
Research
At Bristol-Myers Squibb, patients are at the center of everything we do.
The focus of our research is to increase quality, long-term survival for
patients and make cure a possibility. Through a unique multidisciplinary
approach powered by translational science, we harness our deep
scientific experience in oncology and Immuno-Oncology (I-O) research to
identify novel treatments tailored to individual patient needs. Our
researchers are developing a diverse, purposefully built pipeline
designed to target different immune system pathways and address the
complex and specific interactions between the tumor, its
microenvironment and the immune system. We source innovation internally,
and in collaboration with academia, government, advocacy groups and
biotechnology companies, to help make the promise of transformational
medicines, like I-O, a reality for patients.
About Opdivo
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor
that is designed to uniquely harness the body’s own immune system to
help restore anti-tumor immune response. By harnessing the body’s own
immune system to fight cancer, Opdivo has become an
important treatment option across multiple cancers.
Opdivo’s leading global development program is based on
Bristol-Myers Squibb’s scientific expertise in the field of
Immuno-Oncology, and includes a broad range of clinical trials across
all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical
development program has treated more than 35,000 patients. The Opdivo trials
have contributed to gaining a deeper understanding of the potential role
of biomarkers in patient care, particularly regarding how patients may
benefit from Opdivo across the continuum of PD-L1 expression.
In July 2014, Opdivo was the first PD-1 immune checkpoint
inhibitor to receive regulatory approval anywhere in the world. Opdivo is
currently approved in more than 65 countries, including the United
States, the European Union, Japan and China. In October 2015, the
Company’s Opdivo and Yervoy combination regimen was the
first Immuno-Oncology combination to receive regulatory approval for the
treatment of metastatic melanoma and is currently approved in more than
50 countries, including the United States and the European Union.
U.S. FDA-APPROVED INDICATIONS FOR OPDIVO®
OPDIVO® (nivolumab) as a single agent is indicated for the
treatment of patients with unresectable or metastatic melanoma.
OPDIVO® (nivolumab), in combination with YERVOY®
(ipilimumab), is indicated for the treatment of patients with
unresectable or metastatic melanoma.
OPDIVO® (nivolumab) is indicated for the treatment of
patients with metastatic non-small cell lung cancer (NSCLC) with
progression on or after platinum-based chemotherapy. Patients with EGFR
or ALK genomic tumor aberrations should have disease progression on
FDA-approved therapy for these aberrations prior to receiving OPDIVO.
OPDIVO® (nivolumab) is indicated for the treatment of
patients with metastatic small cell lung cancer (SCLC) with progression
after platinum-based chemotherapy and at least one other line of
therapy. This indication is approved under accelerated approval based on
overall response rate and duration of response. Continued approval for
this indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.
OPDIVO® (nivolumab) is indicated for the treatment of
patients with advanced renal cell carcinoma (RCC) who have received
prior anti-angiogenic therapy.
OPDIVO® (nivolumab), in combination with YERVOY®
(ipilimumab), is indicated for the treatment of patients with
intermediate or poor risk, previously untreated advanced renal cell
carcinoma (RCC).
OPDIVO® (nivolumab) is indicated for the treatment of adult
patients with classical Hodgkin lymphoma (cHL) that has relapsed or
progressed after autologous hematopoietic stem cell transplantation
(HSCT) and brentuximab vedotin or after 3 or more lines of systemic
therapy that includes autologous HSCT. This indication is approved under
accelerated approval based on overall response rate. Continued approval
for this indication may be contingent upon verification and description
of clinical benefit in confirmatory trials.
OPDIVO® (nivolumab) is indicated for the treatment of
patients with recurrent or metastatic squamous cell carcinoma of the
head and neck (SCCHN) with disease progression on or after
platinum-based therapy.
OPDIVO® (nivolumab) is indicated for the treatment of
patients with locally advanced or metastatic urothelial carcinoma who
have disease progression during or following platinum-containing
chemotherapy or have disease progression within 12 months of neoadjuvant
or adjuvant treatment with platinum-containing chemotherapy. This
indication is approved under accelerated approval based on tumor
response rate and duration of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.
OPDIVO® (nivolumab), as a single agent, is indicated for the
treatment of adult and pediatric (12 years and older) patients with
microsatellite instability-high (MSI-H) or mismatch repair deficient
(dMMR) metastatic colorectal cancer (CRC) that has progressed following
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This
indication is approved under accelerated approval based on overall
response rate and duration of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.
Contacts
Bristol-Myers Squibb Company
Media Inquiries:
Ken
Dominski
609-302-3114
[email protected]
Investors:
Tim Power
609-252-7509
[email protected]